July 2015

Teva to Buy Allergan Generics for $40.5 Billion. Teva Pharmaceutical Industries Ltd. said it would buy Allergan PLC’s generics unit for $40.5 billion in cash and stock, in a deal that will vault the Israeli company into the top ranks of global drug makers. Teva said Allergan would receive $33.75 billion in cash and Teva shares valued at $6.75 billion, giving it a 10% stake in Teva. The deal, the latest in a wave of consolidation in the drug industry in recent years, combines Teva, the world’s largest generic-drug company by sales, with the third-largest competitor in the market.

Huge budgets for Cancer Research: relief for patients, investors also gain. Cancer research is a high priority for pharmaceutical companies, and vast amounts of money channeled to investment. It was in May this year, at the annual ASCO International - World's Largest Cancer Research - which was attended by about 30 thousand scientists from around the world. Professor Peter Johnson, a cancer researcher from England declared: "the evidence suggests that we are at the beginning of a whole new era in the treatment of cancer. Professor Johnson was referring to a relatively new treatment for cancer, called immunotherapy. In recent years skepticism of the scientific community about this system was replaced with enthusiasm. The idea underpins this treatment approach is simple, but revolutionary. Immunotherapy actually "teach" the human body to attack cancer cells and destroy malignant tumors, and that by stimulating the natural immune system (Hebrew).
Israeli biotechs scoop $209M as Nasdaq ATM keeps pumping out dollars. A trio of Israeli biotechs have bagged $209 million (€192 million) through share offerings on Nasdaq. Chiasma ($CHMA) led the way with a $101.8 million IPO, trailed by follow-on offerings by NeuroDerm ($NDRM) and RedHill Biopharma ($RDHL) that pulled in $66.9 million and $40 million, respectively.
Israeli placenta-derived cells get nod from top researchers. A new study on Israeli-developed stem cells developed by Israeli biotech Pluristem shows they could help patients suffering from a wide array of physical injuries to live longer and healthier lives. Israeli biotech Pluristem’s off-the-shelf PLacental eXpanded (PLX) cells, derived from harvested human placenta, have already been shown to be effective in ensuring that transplanted organs are assimilated by the body and in reversing nerve damage, and even in helping individuals afflicted with radiation disease recover.
Israeli high-tech frenzy: $6 billion in six months. Business exits come in waves, and we’re in the middle of one. It’s putting hundreds of millions of dollars into the pockets of Israeli entrepreneurs and venture capital funds. On Thursday, Facebook said it was snapping up the Israeli startup Pebbles Interfaces for $85 million. This week came the news that Microsoft was buying the cyber firm Adallom for $320 million, while ad-tech company IronSource was acquiring mobile advertising company Supersonic for between $100 million and $200 million.
Samsung founding startup accelerator in Israel. Samsung is founding a startup accelerator in its development center in the Yakum industrial park. Yossi Smoler, head of the Open Innovation Group at Samsung Electronics Israel R&D center in Yakum, and former director of the incubators program in the Office of the Chief Scientist in the Ministry of the Economy, is in charge of the accelerator.
Invest in health - ensuring Tomorrow, Pharma Israel Conference at the National Economic Conference 2015 of Kalkalist, will take place at the David Intercontinental Hotel, Tel Aviv on September 1, 2015 (Hebrew).
EU will hold a workshop "The regulation of advanced therapies", which will take place on 12-13 October 2015 in Jerusalem.
Now live! Our new translations division of high quality certified medical and pharmaceutical translations. You are welcome to visit our new webpage: www.qt-translations.com